| Epcoritamab studied in …STUDIED_INderived59 of 59show fewer |
|---|
| → studied in | NCT07126236Phase 2 · recruiting Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06045247Phase 2 · recruiting Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · 59 trials list this drug (53 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06672705Phase 1 · recruiting Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783594Phase 2 · not yet recruiting Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06090539Phase 1/Phase 2 · recruiting A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas · 59 trials list this drug (53 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819214Phase 2 · not yet recruiting Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201248Phase 1/Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma · 59 trials list this drug (53 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05206357Phase 1 · active not recruiting Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab · 59 trials list this drug (53 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451810Phase 2 · active not recruiting A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Classic Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05578976Phase 3 · active not recruiting A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma,Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · 59 trials list this drug (53 active) | — | — | Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04623541Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome · 59 trials list this drug (53 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04663347Phase 1/Phase 2 · active not recruiting Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112847Phase 2 · active not recruiting Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · 59 trials list this drug (53 active) | — | — | Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07588698Phase 2 · not yet recruiting Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma · 59 trials list this drug (53 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · 59 trials list this drug (53 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06811272Phase 2 · recruiting Outpatient Epcoritamab in Large B-cell Lymphoma · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191744Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07738887Phase 2 · not yet recruiting Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07082868Phase 1 · recruiting A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) · 59 trials list this drug (53 active) | — | — | Central Nervous System Lymphoma,Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05852717Phase 2 · recruiting Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma · 59 trials list this drug (53 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05409066Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06676033Phase 1 · active not recruiting Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06723457Phase 2 · recruiting Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283720Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma · 59 trials list this drug (53 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05660967Phase 2 · terminated Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06447376Phase 1 · recruiting Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab · 59 trials list this drug (53 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06931652Phase 2 · recruiting Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab · 59 trials list this drug (53 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528352Phase 1 · recruiting External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06458439Phase 2 · recruiting Epcoritamab-CAR T Cells for Large B-cell Lymphomas · 59 trials list this drug (53 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04628494Phase 3 · active not recruiting A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783609Phase 2 · recruiting Epcoritamab and Rituximab for First-line Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848765Phase 2 · recruiting Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy · 59 trials list this drug (53 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226752Phase 3 · active not recruiting A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · 59 trials list this drug (53 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06508658Phase 3 · active not recruiting A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030699Phase 2 · withdrawn A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07451652Phase 2 · recruiting Low Dose Epcoritamab Plus GemOx in R/R DLBCL · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06510361Phase 2 · recruiting Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy · 59 trials list this drug (53 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06510491Phase 2 · recruiting Epcoritamab in Previously Treated WM · 59 trials list this drug (53 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218510Phase 2 · recruiting Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06919939Phase 2 · recruiting Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · 59 trials list this drug (53 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · 59 trials list this drug (53 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07108998Phase 2 · recruiting Study of Epcoritamab as a Consolidation Therapy in CLL/SLL · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796998Phase 2 · recruiting Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · 59 trials list this drug (53 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Splenic Marginal Zone Lymphoma,Marginal Zone Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06414148Phase 2 · recruiting MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma · 59 trials list this drug (53 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04358458Phase 1/Phase 2 · terminated First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06238648Phase 2 · recruiting Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287398Phase 2 · recruiting Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL · 59 trials list this drug (53 active) | — | — | Grade 3 Follicular Lymphoma,High Grade B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05791409Phase 1/Phase 2 · recruiting Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL · 59 trials list this drug (53 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733650approved for marketing Expanded Access Program for Epcoritamab · 59 trials list this drug (53 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05692050no longer available Expanded Access to Epcoritamab · 59 trials list this drug (53 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |